Evaluation of the Efficacy, Safety, and Tolerability of Lacosamide in Major Depressive Episodes of Bipolar Disorder Types I and II.

NCT07412132 · tracked via the Priya Life Science Brazil tracker

Sponsor

University of Sao Paulo

Phase

Phase 3

Started

2026-01-09

Last updated

2026-02-20

Condition(s) studied

Bipolar Affective Disorder

Investigational drug(s) / intervention(s)

Lacosamide →Placebo

Lacosamide: Lacosamide 50mg will be give twice a day por 2 weeks, then Lacosamide 100mg twice a day until the end of the study.

Placebo: Placebo tablets are similar in its features to the active drug, but without any pharmacological agent inside.

Study summary

Initially, observational studies suggested a possible effect of Lacosamide on depressive and anxious symptoms in individuals with epilepsy, and later, an open-label study demonstrated the efficacy of lacosamide in improving depressive and manic symptoms in individuals with bipolar disorder (BD). The primary objective of this study is to evaluate the efficacy of combining lacosamide as an augmentation treatment to first- or second-line medication treatments in moderate to severe major depressive episodes of treatment-resistant BD I and II (failure of at least two adequate treatments during the current episode). The main hypothesis of the study is that lacosamide produces a greater reduction in depression scores compared to a placebo treatment and that both groups will exhibit similar rates of side effects and adverse events. We will conduct a double-blind, randomized, parallel-group pilot study, comparing the enhancement of the treatment that patients had been using with lacosamide and placebo, over a duration of 12 weeks. Forty subjects aged between 18 and 65 years with a diagnosis of BD (I or II) in a moderate or severe major depressive episode, despite the use of first- or second-line treatments, will be selected. The primary outcome will be the assessment of lacosamide efficacy through the difference in scores on the Hamilton Depression Rating Scale (HAMD-17) from the initial visit to the end of week 12 of intervention between the lacosamide and placebo groups.

Eligibility

Sex

ALL

Min age

18 Years

Max age

65 Years

Healthy volunteers

Inclusion Criteria: 1. Diagnosis of bipolar disorder (type I or II) confirmed by structured clinical interview; 2. acute major depressive episode of moderate or severe intensity; 3. no response to at least two adequate pharmacological interventions to treat the current episode. Exclusion Criteria: 1. Current diagnosis of schizophrenia, dementia, intellectual disability, organic mental disorder (by clinical assessment). Comorbidity with other psychiatric disorders (personality disorders, anxiety disorders, substance use disorders, eating disorders, and attention deficit disorder) will be permitted provided the primary diagnosis is bipolar disorder; 2. acute suicidal ideation (defined by HAMD-17 item 3 ≥ 3 points or by clinical assessment); 3. current depressive episode with psychotic features (by clinical assessment); 4. suspected or confirmed pregnancy; 5. severe or unstable clinical illnesses; 6. previous history of non-response to an adequate course of at least 8 sessions of electroconvulsive therapy; 7. previous history of non-response to an adequate course of ketamine treatment.

Primary outcome measure(s)

Primary outcome — week 12
The efficacy of lacosamide assessed by the difference in Hamilton Depression Scale score from the initial visit to the end of week 12 of the intervention between the lacosamide and placebo groups. Minimum: 0 point Maximum: 50 points. The increase in the pontuation of the scale is related to worse outcomes.

Trial sites (1)

Facility	City	Region	Status
Instituto de Psiquiatia (IPQ)	São Paulo	São Paulo	Recruiting

More University of Sao Paulo trials in Brazil

Performance of Next-X in Alveolar Ridge Preservation Recruiting

SBRT for Hepatocellular Carcinoma Patients With Partial Response to TACE Active, not recruiting

Effects of Periodontitis on Heart Rate Variability Active, not recruiting

Foam Sclerotherapy With or Without Transdermal Laser for Reticular Veins and Telangiectasias Active, not recruiting

Ayahuasca, Esketamine and Body Image Perception Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07412132 on ClinicalTrials.gov ↗ ← All trials in Brazil